& Shi, Y
[1] [2] When treatment is interrupted for extended periods, the body may lose its adaptation to the medication, and restarting at a full maintenance dose could increase the risk of gastrointestinal symptoms
The combination therapy of GLP-1 receptor agonists and metformin demonstrates superior safety over monotherapy, while revealing novel adverse events and demographic-specific risk patterns, thereby offering reliable evidence to inform clinical practice
nausea at elevated doses (anecdotal, human) injection site discomfort (anecdotal) Where to source Research use only Affiliate link we may earn a commission at no extra cost to you
For BPC-157, agency scientists raised concerns about the lack of clinical trial evidence and unresolved questions about the chemical identity of the substance
The picture remains incomplete, however, when assessing the mechanism by which this is achieved and if these cardiovascular effects can be generalized for the entire class of drugs